{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:23:37Z","timestamp":1787765017707,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Information on genotypic with comparison of phenotypic drug sensitivity test of anti-tuberculosis (TB) has been reported in several studies, which have variable results. The present study aimed to assess the Genotype MTBDRsl version 2.0\/Line probe assay (LPA) for the detection of fluoroquinolones (FQ) and aminoglycosides (AMGs) resistance mutations among drug-resistant\n                      <jats:italic toggle=\"yes\">Mycobacterium<\/jats:italic>\n                      TB (MTB) strains and also to compare the patterns of genotypic mutations of gyrA\/B,\n                      <jats:italic toggle=\"yes\">rrs<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">eis<\/jats:italic>\n                      with mycobacteria growth indicator tube (MGIT 960).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 1416 samples were subjected to Genotype MTBDRsl version 2.0 assay. One hundred and twenty sputum smear positive MTB isolates and 37 sputum smear negative MTB isolates confirmed multiple drug resistance resistant to FQ and AMG by the Genotype MTBDRsl version 2.0 were subjected to phenotypic drug susceptibility testing (DST) were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The association sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for the resistance detection between MGIT (DST) and the Genotype MTBDRsl version 2.0 assay was significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) of moxifloxacin (MFX) concentration. Sensitivity and specificity value for kanamycin (KAN) resistance was 76% and 89%; 47% and 94% for capreomycin (CAP); and 60% and 76% for low-level KAN, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Our results indicate that MFX (0.25and 1 \u03bcg\/mL), KAN (2.5 \u03bcg\/mL), and CAP (2.5 \u03bcg\/mL) significantly (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) and support the World Health Organization guidance to test FQ and AMG by genotypic test.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_120_23","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:00:30Z","timestamp":1741140030000},"page":"299-304","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Genotype MTBDRsl Version 2 and Phenotypic Drug Resistance Detection of Mycobacterium tuberculosis for Fluoroquinolones and Aminoglycosides"],"prefix":"10.4103","volume":"12","author":[{"given":"Ramalingam","family":"Radhakrishnan","sequence":"first","affiliation":[{"name":"ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Prabuseenivasan","sequence":"additional","affiliation":[{"name":"ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hannah","sequence":"additional","affiliation":[{"name":"ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Vaishanavee","sequence":"additional","affiliation":[{"name":"ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Senthildevi","sequence":"additional","affiliation":[{"name":"ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kannadhasan","sequence":"additional","affiliation":[{"name":"ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Suchithra","sequence":"additional","affiliation":[{"name":"ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Rajendran","sequence":"additional","affiliation":[{"name":"ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponnuraja","family":"Chinnaiyan","sequence":"additional","affiliation":[{"name":"ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Jayabal","sequence":"additional","affiliation":[{"name":"District TB Centre, National TB Elimination Programme, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Frederick","sequence":"additional","affiliation":[{"name":"State TB Cell, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9203-2664","authenticated-orcid":false,"given":"Sivakumar","family":"Shanmugam","sequence":"additional","affiliation":[{"name":"ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"R2-20250306","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/2212-5531.307131","article-title":"New drugs and treatment recommendations \u2013What are the consequences at the TB-laboratory","volume":"9","author":"Hoffner","year":"2021","journal-title":"Int J Mycobacteriol"},{"key":"R3-20250306","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/ijmy.ijmy_135_18","article-title":"Meta-narrative review of molecular methods for diagnosis and monitoring of multidrug-resistant tuberculosis treatment in adults","volume":"7","author":"Mbelele","year":"2018","journal-title":"Int J Mycobacteriol"},{"key":"R6-20250306","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3201\/eid2509.190105","article-title":"Limited scope of shorter drug regimen for MDR TB caused by high resistance to fluoroquinolone","volume":"25","author":"Singh","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"R7-20250306","doi-asserted-by":"crossref","first-page":"e67030","DOI":"10.1371\/journal.pone.0067030","article-title":"Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients","volume":"8","author":"Jawahar","year":"2013","journal-title":"PLoS One"},{"key":"R8-20250306","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/ijmy.ijmy_59_17","article-title":"Treatment outcome of patients having extensively drug-resistant tuberculosis in Gujarat, India","volume":"6","author":"Prajapati","year":"2017","journal-title":"Int J Mycobacteriol"},{"key":"R11-20250306","year":"2015","journal-title":"GenoType MTBDRsl VER 2.0 b AU7 Instructions for Use. Document IFU-317A-01"},{"key":"R17-20250306","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jgar.2020.11.011","article-title":"Fluroquinolone drug resistance among MDR-TB patients increases the risk of unfavourable interim microbiological treatment outcome:An observational study","volume":"24","author":"Singh","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"R18-20250306","doi-asserted-by":"crossref","first-page":"536","DOI":"10.5588\/ijtld.15.0562","article-title":"Treatment as diagnosis and diagnosis as treatment:Empirical management of presumptive tuberculosis in India","volume":"20","author":"McDowell","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"R19-20250306","doi-asserted-by":"crossref","first-page":"e12023","DOI":"10.1371\/journal.pone.0012023","article-title":"Tuberculosis management by private practitioners in Mumbai, India:Has anything changed in two decades?","volume":"5","author":"Udwadia","year":"2010","journal-title":"PLoS One"},{"key":"R20-20250306","doi-asserted-by":"crossref","first-page":"e0120470","DOI":"10.1371\/journal.pone.0120470","article-title":"Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates:A systematic review","volume":"10","author":"Avalos","year":"2015","journal-title":"PLoS One"},{"key":"R21-20250306","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/ijmy.ijmy_70_22","article-title":"Diagnostic utility of GenoType MTBDRsl assay for the detection of moxifloxacin-resistant Mycobacterium tuberculosis, as compared to phenotypic method and whole-genome sequencing","volume":"11","author":"Yadav","year":"2022","journal-title":"Int J Mycobacteriol"},{"key":"R22-20250306","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/mdr.2020.0240","article-title":"Emergence of specific gyrA mutations associated high-level fluoroquinolone-resistant Mycobacterium tuberculosis among multidrug-resistant tuberculosis cases in North India","volume":"27","author":"Singh","year":"2021","journal-title":"Microb Drug Resist"},{"key":"R23-20250306","doi-asserted-by":"crossref","first-page":"e0229419","DOI":"10.1371\/journal.pone.0229419","article-title":"Performance of genotype MTBDRsl V2.0 over the genotype MTBDRsl V1 for detection of second line drug resistance:An Indian perspective","volume":"15","author":"Rufai","year":"2020","journal-title":"PLoS One"},{"key":"R24-20250306","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2991\/j.jegh.2018.02.100","article-title":"Genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis from the Northern region of India","volume":"8","author":"Yadav","year":"2018","journal-title":"J Epidemiol Glob Health"},{"key":"R25-20250306","doi-asserted-by":"crossref","first-page":"e33275","DOI":"10.1371\/journal.pone.0033275","article-title":"Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin:A systematic review","volume":"7","author":"Georghiou","year":"2012","journal-title":"PLoS One"},{"key":"R26-20250306","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijmyco.2015.09.001","article-title":"Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables","volume":"5","author":"Kambli","year":"2016","journal-title":"Int J Mycobacteriol"},{"key":"R28-20250306","doi-asserted-by":"crossref","first-page":"e0261329","DOI":"10.1371\/journal.pone.0261329","article-title":"Performance of GenoType MTBDRsl assay for detection of second-line drugs and ethambutol resistance directly from sputum specimens of MDR-TB patients in Bangladesh","volume":"16","author":"Rahman","year":"2021","journal-title":"PLoS One"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_120_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:55:07Z","timestamp":1787763307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_120_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_120_23","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2023-05-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}